Polo-like Kinase 1 Inhibition as a Therapeutic Approach to Selectively Target BRCA1-Deficient Cancer Cells by Synthetic Lethality Induction.
Carbajosa S, Pansa MF, Paviolo NS, Castellaro AM, Andino DL, Nigra AD, García IA, Racca AC, Rodriguez-Berdini L, Angiolini V, Guantay L, Villafañez F, Federico MB, Rodríguez-Baili MC, Caputto BL, Drewes G, Madauss KP, Gloger I, Fernandez E, Gil GA, Bocco JL, Gottifredi V, Soria G.
Carbajosa S, et al.
Clin Cancer Res. 2019 Jul 1;25(13):4049-4062. doi: 10.1158/1078-0432.CCR-18-3516. Epub 2019 Mar 19.
Clin Cancer Res. 2019.
PMID: 30890549